HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 288/4/H1851    most recent 00362.2004v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (18) Citing Articles via Google Scholar Google Scholar Articles by Glover, D. K. Articles by Beller, G. A. Search for Related Content PubMed PubMed Citation Articles by Glover, D. K. Articles by Beller, G. A.

Reduction of infarct size and postischemic inflammation from ATL-146e, a highly selective adenosine A_2A receptor agonist, in reperfused canine myocardium

Departments of ¹Internal Medicine and ²Chemistry, Experimental Cardiology Laboratory, Cardiovascular Division, University of Virginia Health System, Charlottesville, Virginia

Submitted 14 April 2004 ; accepted in final form 1 December 2004

Adenosine and adenosine A_2A receptor agonists have been shown to limit myocardial infarct size when given at vasodilatory doses during reperfusion. This beneficial effect is thought to be due, in part, to stimulation of adenosine A_2A receptors on inflammatory cells. The specific aims of this study were to determine whether the anti-inflammatory and cardioprotective properties of a novel adenosine A_2A receptor agonist, ATL-146e (ATL), alone or in combination with the phosphodiesterase IV inhibitor rolipram would occur using very low, nonvasodilating doses. In a canine model of reperfused myocardial infarction, low-dose ATL given alone reduced infarct size by 45% (P < 0.05 vs. control). When ATL was combined with a very low dose of rolipram (0.001 µg·kg^–1·min^–1), a marked reduction in P-selectin expression and neutrophil infiltration (51% lower; P < 0.001 vs. control) was seen and the infarct size reduction (58% lower; P < 0.01 vs. control) was greater than observed with ATL (45% lower; P < 0.05) or rolipram (33% lower; P < 0.05) alone. In conclusion, a low, nonvasodilating dose of ATL, a highly selective adenosine A_2A receptor agonist, reduced infarct size after reperfusion. Furthermore, combining ATL and the phosphodiesterase IV inhibitor rolipram reduced infarct size even more than either agent alone. Such combination therapy may be beneficial clinically by potentiating cardioprotection after coronary reperfusion at doses far below those producing vasodilatation or side effects.

myocardial infarction

This article has been cited by other articles:

				T. C. Lisle, L. M. Gazoni, L. G. Fernandez, A. K. Sharma, A. M. Bellizzi, G. D. Schifflett, V. E. Laubach, and I. L. Kron Inflammatory lung injury after cardiopulmonary bypass is attenuated by adenosine A(2A) receptor activation. J. Thorac. Cardiovasc. Surg., November 1, 2008; 136(5): 1280 - 1288. [Abstract] [Full Text] [PDF]

				L. M. Gazoni, V. E. Laubach, D. P. Mulloy, A. Bellizzi, E. B. Unger, J. Linden, P. I. Ellman, T. C. Lisle, and I. L. Kron Additive protection against lung ischemia-reperfusion injury by adenosine A2A receptor activation before procurement and during reperfusion J. Thorac. Cardiovasc. Surg., January 1, 2008; 135(1): 156 - 165. [Abstract] [Full Text] [PDF]

				D. K. Glover, M. Ruiz, K. Takehana, F. D. Petruzella, J. M. Rieger, T. L. Macdonald, D. D. Watson, J. Linden, and G. A. Beller Cardioprotection by adenosine A2A agonists in a canine model of myocardial stunning produced by multiple episodes of transient ischemia Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H3164 - H3171. [Abstract] [Full Text] [PDF]

				J. J. Pacella and F. S. Villanueva Effect of Coronary Stenosis on Adjacent Bed Flow Reserve: Assessment of Microvascular Mechanisms Using Myocardial Contrast Echocardiography Circulation, October 31, 2006; 114(18): 1940 - 1947. [Abstract] [Full Text] [PDF]

				I. C. Cavalcante, M. V. Castro, A. R. F. Barreto, G. W. Sullivan, M. Vale, P. R. C. Almeida, J. Linden, J. M. Rieger, F. Q. Cunha, R. L. Guerrant, et al. Effect of Novel A2A Adenosine Receptor Agonist ATL 313 on Clostridium difficile Toxin A-Induced Murine Ileal Enteritis. Infect. Immun., May 1, 2006; 74(5): 2606 - 2612. [Abstract] [Full Text] [PDF]

				R. F. Bonvini, T. Hendiri, and E. Camenzind Inflammatory response post-myocardial infarction and reperfusion: a new therapeutic target? Eur. Heart J. Suppl., October 1, 2005; 7(suppl_I): I27 - I36. [Abstract] [Full Text] [PDF]